Ποια είναι η τιμή για TTY Biopharm Company Limited (4105)

Η τιμή για TTY Biopharm Company Limited (4105) είναι $2.47

Ποια είναι η κεφαλαιοποίηση αγοράς για TTY Biopharm Company Limited (4105)

Η κεφαλαιοποίηση αγοράς για TTY Biopharm Company Limited (4105) είναι $615.15M

TTY Biopharm Company Limited (4105) Τιμή και Κεφαλαιοποίηση Αγοράς

TTY Biopharm Company Limited, along with its associated entities, specializes in the creation and distribution of pharmaceutical and chemical products across Taiwan and global markets. Its operations are structured into several key divisions: Oncology, Intensive Care, Healthcare, Export & CDMO, and an "Other" Business Unit. For anti-cancer and supportive therapies, the company markets a range of oncology medications under prominent brand names such as Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre. Addressing infectious diseases and influenza, TTY Biopharm supplies anti-infection drugs including Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax. Furthermore, the firm offers various healthcare-related pharmaceuticals designed for the digestive system, osteoporosis, and metabolic conditions, marketed under brands like Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin. Beyond pharmaceuticals, the company is also involved in distributing functional foods, conducting international trade (import/export), and engaging in investment ventures. Established in 1960, TTY Biopharm maintains its principal office in Taipei, Taiwan.

Η τιμή για 4105	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$21,169.79 $615.15M	NVDA	$5.264T	+855,603.14%
$18,907.21 $615.15M	AAPL	$4.701T	+764,147.27%
$16,799.43 $615.15M	GOOG	$4.177T	+678,949.00%
$15,352.51 $615.15M	MSFT	$3.817T	+620,463.10%
$11,527.60 $615.15M	AMZN	$2.866T	+465,856.51%

Η τιμή για 4105

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$21,169.79 $615.15M